Even in the face of Brazil's economic instability, the pharmaceutical industry stood out and continued to rise in the economic market. This growth was driven by increased life expectancy, greater health concerns, technological advances, growth in the generics market, competitive industry management, new product launches, advances in biotechnology, mergers and acquisitions, among other factors.

Growth of the Pharmaceutical Industry

The integration of these factors resulted in a favorable scenario for the growth of the sector. According to data from the 2017 Guide of the Pharmaceutical Research Industry Association (Interfarma), Brazil occupies the 8th position in the world ranking of the pharmaceutical market. The expectation is that in 2021 the country will reach the mark of 5th largest pharmaceutical industrial market in the world.

The 2016 Pharmaceutical Market Statistical Yearbook , published by the National Health Surveillance Agency (Anvisa), reported that the pharmaceutical industry recorded revenues of R$ 63.5 billion in Brazil with the sale of 4.5 billion product packages in 2016

The commercialization of generic drugs reached the leadership in sales volume in Brazil, representing 32.4% of the market. Sales of similar drugs took the second position with 31.5% of sales. Of the 20 companies with the highest revenue, eight are Brazilian.

Pharmaceutical industry challenges

For the sector to continue with its accelerated growth, the pharmaceutical industries need to have efficient management and qualified leadership to manage the challenges of this market with great opportunities for growth.

In addition to solid investments, it is essential to manage the factors that significantly influence the industrial scenario, such as the rise in the dollar, which directly impacts the acquisition of imported inputs and the increase in production costs. Industries increasingly need efficient, effective, innovative production processes and qualified professionals to produce high quality medicines at a profitable operating cost.

New directions for continued growth

The market is dynamic and requires pharmaceutical industries to have an intelligent vision to continue growing and reaping great results in the future. For this, it is necessary to follow the movement, market needs and outline new directions for the trends that will emerge.

Currently, the blockbusters of the pharmaceutical industry, leading drugs in sales, are generics and the like. And in a few years, will this scenario remain?

According to the study “The Future of Brazilian Pharmaceutical Laboratories” by the consulting firm Boston Consulting Group (BCG), industries already need to look for new alternatives to add and continue the growth of the sector and there are at least seven possible ways for the sector expand in the future. Check out:

  1. Development of biological medicines;
  2. Development of biosimilar medicines;
  3. Incremental innovation, through the development of improvements to a product or new applications for molecules that already exist;
  4. Radical innovation, through the development of new products;
  5. Consolidation and joining of forces between the generic manufacturing industries;
  6. Internationalization of the operations of Brazilian industries;
  7. Diversification and expansion of the portfolio;

Galantamine EP Impurity C

Galantamine EP Impurity D

Galantamine EP Impurity E

Galantamine EP Impurity F